Edition:
United Kingdom

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

406.35INR
10:13am GMT
Change (% chg)

Rs-8.50 (-2.05%)
Prev Close
Rs414.85
Open
Rs415.00
Day's High
Rs416.55
Day's Low
Rs405.25
Volume
1,816,421
Avg. Vol
1,132,048
52-wk High
Rs560.00
52-wk Low
Rs328.80

Select another date:

Fri, Dec 8 2017

BRIEF-Cadila Healthcare's Zydus Gets Final Nod From U.S. FDA For Clozapine Tablets

* SAYS ZYDUS GET FINAL NOD FROM U.S. FDA FOR CLOZAPINE TABLETS USP

BRIEF-Cadila Healthcare Says Zydus Gets Tentative Approval From U.S. FDA For Pregabalin Capsules

* SAYS ZYDUS GETS TENTATIVE APPROVAL FROM U.S. FDA FOR PREGABALIN CAPSULES

BRIEF-Cadila Healthcare's Zydus, ICMR Launch Diagnostic Kits To Detect Rare Infectious Diseases

* INDIAN COUNCIL OF MEDICAL RESEARCH, ZYDUS LAUNCH DIAGNOSTIC KITS TO DETECT NEGLECTED INFECTIOUS DISEASES IN LIVESTOCK

BRIEF-Cadila Healthcare Says ‍Zydus Gets Final Nod From U.S. FDA For Candesartan Cilexetil And Hydrochlorothiazide Tablets​

* SAYS ‍ZYDUS GETS FINAL APPROVAL FROM U.S. FDA FOR CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS

BRIEF-Cadila Healthcare's ‍Zydus Gets Nod For Topiramate Extended-Release Capsules​

* ‍ZYDUS GETS FINAL APPROVAL FROM U.S. FDA FOR TOPIRAMATE EXTENDED-RELEASE CAPSULES

BRIEF-Zydus Cadila's anemia developmental candiate ZYAN1 named as Desidustat by WHO‍​

* WHO INN committee grants name Desidustat to Zydus Cadila's phase II anemia candidate, Zyan1‍​

BRIEF-India's Cadila Healthcare Sept-qtr consol profit up about 32 pct

* Sept quarter consol net profit 5.03 billion rupees versus profit of 3.80 billion rupees last year

BRIEF-Cadila Healthcare clarifies that co only distributes hypertension drug mentioned in news article

* Clarifies on news item, "‍Zydus Cadila, Intas under scanner for launching hypertension drug without permit​"

BRIEF-Cadila Healthcare's Zydus gets U.S. FDA nod for drug to treat depression

* ‍Zydus receives final approval from U.S. FDA for Desvenlafaxine extended-release tablets, which are used to treat major depression

BRIEF-Cadila Healthcare's Zydus gets final U.S.FDA nod for desmopressin nasal spray solution​

* Says Zydus gets final u.s. Fda nod for desmopressin nasal spray solution ​ Source text: http://bit.ly/2fO3mIi Further company coverage:

Select another date: